PURPOSE The trial was undertaken to determine (1) the relative efficacy/toxicity of two
commonly used combination chemotherapy regimens in patients with extensive small-cell …

The Southwest Oncology Group (SWOG) has conducted a phase II study to explore the
efficacy and toxicity of initial, concurrent use of radiation therapy with cisplatin, etoposide …

Eighteen patients with histologically documented small cell carcinoma of the lung who had
failed initial combination chemotherapy regimens were treated with single-agent cisplatin in …

Between March 1986 and May 1988, the Southwest Oncology Group enrolled 58 previously
untreated patients with limited small-cell lung cancer on a treatment program that …

PURPOSE The antineoplastic activity of carboplatin and etoposide may be improved by the
addition of vincristine (CEV) because of its low myelosuppressive potential and its activity in …

7050 Background: Preclinical studies have demonstrated VEGF expression in SCLC, a
target that may predict response to treatment with anti-angiogenic agents such as B. Few …

Based upon the schedule specificity of etoposide and the in vitro and clinical synergy
sbserved with cisplatin, the Eastern Cooperative Oncology Group conducted a phase II trial …

Opinion statement Small cell lung cancer (SCLC) is an aggressive type of lung cancer
characterized by rapid growth and early metastasis. It is chemosensitive and radiosensitive …

Abstract A comparison of CTX+ CCNU and CTX+ CCNU+ procarbazine as initial systemic
treatment was made in 440 evaluable patients with small‐cell carcinoma of the lung. The …

Aims and background There has been a trend to replace cisplatin with carboplatin in the
treatment of small-cell lung carcinoma. The goal of the present study was to determine the …